ozekibart

Ozekibart is a next-generation, recombinant, humanized, tetravalent monoclonal antibody that acts as an agonist of death receptor 5 (DR5), also known as TRAIL receptor 2. It is based on a single-domain antibody platform and is precisely engineered to promote tumor-biased cell death by activating DR5. Ozekibart induces potent DR5 receptor clustering and subsequent activation of apoptosis in cancer cells while sparing healthy cells. The drug has been designed to achieve optimal DR5 agonism and safety, including features to reduce recognition by pre-existing antidrug antibodies and minimize toxic hyperclustering. Ozekibart is being developed primarily for the treatment of unresectable or metastatic conventional chondrosarcoma (with orphan drug status) and is also under investigation for other solid tumors such as colorectal adenocarcinoma and Ewing sarcoma[1][2][4][5][6][7].

Brand names

ozekibart

Other names

ozekibartINBRX-109INBRX109INBRX 109JCT-205JCT205JCT 205